[A24-81] Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35
Last updated 19.09.2024
Project no.:
A24-81
Commission:
Commission awarded on 06.08.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with relapsed and refractory multiple myeloma who have received prior therapies and have demonstrated disease progression on the last therapy; pretreatment includes an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody
- Patients with 2 to 3 prior therapies: Unchanged after addendum: added benefit not proven
- Patients with at least 4 prior therapies: Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-81_en
| Project no. | Title | Status |
|---|---|---|
| A24-35 | Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-09-19 A G-BA decision was published.